We found that calcitonin gene-related peptide (CGRP) enhanced the expression of levels of serum amyloid A (SAA) and interleukin-6 (IL-6) in HepG2. In addition, CGRP-induced SAA1/2 mRNA expression was blocked by an anti-IL-6 neutralizing antibody in HepG2. These results suggest that CGRP promotes SAA synthesis through activation of IL-6 in human hepatocytes.
Serum amyloid A (SAA) is the circulating precursor of amyloid A protein, the fibrillar component of amyloid deposits. 1, 2) In humans, four SAA genes have been identified. Two genes (SAA1 and SAA2) encode acutephase SAA (A-SAA), and are coordinately induced in response to inflammation. SAA1 and SAA2 are 95% homologous in both coding and noncoding regions. SAA3 is a pseudo gene. SAA4 encodes constitutive SAA and is minimally inducible. A-SAA dramatically increases during acute inflammation as compared with normal status. 3, 4) A-SAA is synthesized mainly in the liver, 5) and regulation of A-SAA genes is set in motion by the secretion of pro-inflammatory cytokines, such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-(TNF). 6) These cytokines are regulated by several factors. One of these is calcitonin gene-related peptide (CGRP), [7] [8] [9] [10] but the relationship between CGRP and A-SAA remains unknown.
CGRP is a 37-amino acid neuropeptide first found in humans, and mammals in 1982. 11) CGRP, a potent vasodilatory peptide present in central and peripheral neurons, is released at systematic and local inflammatory sites. 12) Several studies have found that the release and synthesis of CGRP mediates pro-inflammatory responses in several types of cells, [7] [8] [9] [10] but its effects in hepatocytes remain unclear. Hence we examined the effects of CGRP on A-SAA synthesis and attempted to determine whether pro-inflammatory cytokines is related to its regulation in HepG2 cells.
HepG2 cells were maintained in Dulbecco's modified Eagle's medium Nutrient Mixture F-12 (DMEM-F12 HAM) (Sigma-Aldrich, St. Louis, MO) supplemented with 10% (v/v) fetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS). The cells were seeded at 5 Â 10 5 cells/well in 48-well plates and cultured in a humidified atmosphere of 5% CO 2 at 37 C until subconfluent. After serum starvation for 24 h, the cells were treated with and without CGRP (100 nM) (R&D Systems, Minneapolis, MN) for 0, 1, 2, 4, 8, 12, and 24 h. Moreover, subconfluent cells were treated with CGRP (100 nM) and an anti-IL-6 neutralizing antibody (0.1 or 1 mg/mL) (R&D Systems) for 4 h. Following these treatments, total RNA was extracted by the SV Total RNA Isolation System (Promega, Madison, WI). The total RNA samples were stored at À80 C until use. To synthesize cDNA, 2 mg of total RNA was reverse transcribed with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) following the manufacturer's instructions. Primers and probes for human Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), IL-1, IL-6, TNF and SAA1/2 were purchased from Applied Biosystems as Assays-on-Demand primer/probe gene expression products. Realtime PCR was performed on an ABI PRISM 7300 Sequence Detection System with THUNDERBIRDÔ Probe qPCR Mix (Toyobo, Osaka, Japan), primers, and probes. PCR amplification was done in duplicate wells in the same 96-well plate under the following conditions: 2 min at 50 C and 10 min at 95 C, followed by 50 cycles of 15 s at 95 C and 1 min at 60 C. The mRNA levels of the targets were expressed as values relative to those of human GAPDH.
The culture supernatant fraction was collected after 24 h of incubation with and without CGRP (10 or 100 nM). The level of SAA was measured with a SAA Human ELISA kit (Life Technologies, Carlsbad City, CA) following to the manufacturer's instructions.
Data were expressed as mean AE standard deviation (SD). The mean of multiple groups was compared by Tukey's multiple comparison test following one-way analysis of variance by SPSS 21.0J. All results at p < 0:05 were taken to be statistically significant.
This study indicates that the level of SAA1/2 mRNA in the CGRP group was significantly higher than that of the vehicle at 4 h (Fig. 1A) . Furthermore, stimulation by CGRP (100 nM) significantly increased SAA protein level (Fig. 1B) . Gene expression of SAA is regulated by IL-1, IL-6, and TNF in hepatocytes. 13) Some studies have found that CGRP regulated the expression of IL-1 and IL-6 in macrophages 7, 8) and TNF in bone marrow 9) and osteoblasts. 10) Hence, we investigated to determine whether stimulation by CGRP would raise the levels of IL-1, IL-6, and TNF mRNAs in hepatocytes. CGRP treatment did not change the mRNA levels of IL-1 and y To whom correspondence should be addressed. Tel/Fax: +81-3-5477-2458; E-mail: y3oishi@nodai.ac.jp Biosci. Biotechnol. Biochem., 77 (10), [2151] [2152] [2153] 2013 Note TNF as compared to vehicle ( Fig. 2A and B ). On the other hand, stimulation by CGRP had significantly increased the level of IL-6 mRNA at 2 h (Fig. 2C) . These results showed that CGRP promoted SAA synthesis through IL-6 activation in hepatocytes, but the reason CGRP did not affect IL-1 or the TNF mRNA levels in this study is unclear. To clarify this, further studies are necessary.
Next, in order to ascertain whether increased SAA is mediated by IL6, cells were treated with CGRP in the presence of the anti-IL-6 neutralizing antibody. The IL-6 mRNA level induced by CGRP addition was inhibited by adding the neutralizing antibody (Fig. 3) . These data indicate that CGRP upregulated the level of SAA via activation of IL-6 in human hepatocytes. Aiyar et al. 14) found that CGRP receptors in most tissues and cell lines are coupled to the G-proteins family of heterotrimeric G-protein, and that stimulation of CGRP increased intracellular cAMP levels. Yu et al. 15) also found that cAMP can potentiate IL-6 production in hepatocytes. Thus the increased SAA level may have resulted from an increase in IL-6 level through activation of cAMP.
In conclusion, we found that CGRP promotes SAA synthesis through IL-6-dependent pathway in human hepatocytes. This is the first study to find that CGRP acts indirectly on SAA1/2 gene expression via activation of IL-6 to promote SAA protein synthesis in human hepatocytes. Recober et al. 16) showed that obesity enhanced the production of CGRP. In addition, the gene expression of adiponectin, which is inversely correlated with increases in adipose tissues, was downregulated in adipocytes treated with recombinant A-SAA. 17) Decreases in adiponectin levels induced by obesity cause insulin resistance and arteriosclerosis. 18) In sum, SAA induced by CGRP in hepatocytes can cause such negative impacts through decreases in adiponectin. We hope that our study will lead to elucidation of the physiological action of CGRP.
